Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

NCT02572817 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

138

Enrollment

NIH

Sponsor class

Conditions

Influenza A Virus Infection

Interventions

BIOLOGICAL: High-titer anti-influenza plasma
BIOLOGICAL: Low-titer anti-influenza plasma

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)